A Case of Systemic Lupus Erythematosus-Associated Hemophagocytic Lymphohistiocytosis Treated Successfully with an Etoposide Infusion / 대한내과학회지
Korean Journal of Medicine
; : 613-618, 2013.
Article
en Ko
| WPRIM
| ID: wpr-80224
Biblioteca responsable:
WPRO
ABSTRACT
Hemophagocytic lymphohistiocytosis (HLH) can develop following strong activation of the immune system and the cardinal symptoms are a prolonged fever, hematological abnormalities, hepatosplenomegaly, and hemophagocytosis. HLH can be classified as primary or secondary HLH, associated with infections, malignancy and autoimmune disease. There is no consensus on the primary treatment regimen in systemic lupus erythematosus (SLE)-associated HLH. We experienced a case of SLE-associated HLH in a previously healthy adult. She was initially treated with intravenous immunoglobulin, cyclosporine, and high-dose steroid, but had a poor clinical response. After intravenous etoposide, the patient stabilized and has been followed for 1 year without reactivation of the HLH or SLE.
Palabras clave
Texto completo:
1
Base de datos:
WPRIM
Asunto principal:
Enfermedades Autoinmunes
/
Inmunoglobulinas
/
Ciclosporina
/
Consenso
/
Linfohistiocitosis Hemofagocítica
/
Etopósido
/
Fiebre
/
Sistema Inmunológico
/
Lupus Eritematoso Sistémico
Tipo de estudio:
Guideline
Límite:
Adult
/
Humans
Idioma:
Ko
Revista:
Korean Journal of Medicine
Año:
2013
Tipo del documento:
Article